(AXSM) Axsome Therapeutics - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 11.664m USD | Total Return: 112.9% in 12m

Antidepressants, Sleep Medications, Migraine Treatments, Fibromyalgia Drugs
Total Rating 37
Safety 38
Buy Signal 0.27
Biotechnology
Industry Rotation: -12.2
Market Cap: 11.7B
Avg Turnover: 141M
Risk 3d forecast
Volatility41.0%
VaR 5th Pctl6.50%
VaR vs Median-3.62%
Reward TTM
Sharpe Ratio1.92
Rel. Str. IBD91.9
Rel. Str. Peer Group81.4
Character TTM
Beta0.410
Beta Downside0.109
Hurst Exponent0.350
Drawdowns 3y
Max DD36.45%
CAGR/Max DD1.38
CAGR/Mean DD3.75
EPS (Earnings per Share) EPS (Earnings per Share) of AXSM over the last years for every Quarter: "2021-03": -0.78, "2021-06": -0.86, "2021-09": -0.93, "2021-12": -0.9, "2022-03": -1.03, "2022-06": -1.06, "2022-09": -1.07, "2022-12": -1.41, "2023-03": -0.26, "2023-06": -1.54, "2023-09": -1.32, "2023-12": -2.08, "2024-03": -1.44, "2024-06": -1.67, "2024-09": -1.3419, "2024-12": -1.54, "2025-03": -1.2157, "2025-06": -0.97, "2025-09": -0.95, "2025-12": -0.56, "2026-03": -1.26,
Last SUE: -2.52
Qual. Beats: -1
Revenue Revenue of AXSM over the last years for every Quarter: 2021-03: 0, 2021-06: 0, 2021-09: 0, 2021-12: 0, 2022-03: 0, 2022-06: 8.82, 2022-09: 16.846, 2022-12: 24.371528, 2023-03: 94.576, 2023-06: 46.7, 2023-09: 57.794, 2023-12: 71.53, 2024-03: 74.999, 2024-06: 87.166, 2024-09: 104.762, 2024-12: 118.766, 2025-03: 121.463, 2025-06: 150.042, 2025-09: 170.992, 2025-12: 195.999, 2026-03: 191.203,
Rev. CAGR: 61.29%
Rev. Trend: 99.4%
Last SUE: 0.12
Qual. Beats: 0

Warnings

Interest Coverage Ratio -34.1 is critical

Altman Z'' -8.72 < 1.0 - financial distress zone

Tailwinds

Supp Ema20, Leader

Description: AXSM Axsome Therapeutics

Axsome Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system (CNS) disorders. Its current commercial portfolio includes Auvelity for major depressive disorder and Sunosi for excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea. The company operates within the high-barrier CNS sector, where drug development often requires navigating complex regulatory pathways and multi-mechanistic pharmacological profiles.

The company maintains an extensive clinical pipeline, including AXS-07 for acute migraine treatment and several late-stage candidates. Notable investigational assets include AXS-05 for Alzheimer’s disease agitation and smoking cessation, AXS-12 for narcolepsy, and AXS-14 for fibromyalgia. Most biopharmaceutical firms in this stage utilize a research-heavy business model, frequently partnering with academic institutions like Duke University to validate therapeutic efficacy through multi-phase clinical trials.

Investors may find additional data points on these clinical developments by exploring the resources at ValueRay. Based in New York, Axsome continues to transition from a development-stage entity to a fully integrated commercial organization by expanding the indications for its existing molecular compounds.

Headlines to Watch Out For
  • Auvelity prescription growth and market share expansion drive primary revenue growth
  • Sunosi label expansion into ADHD and binge eating disorders increases addressable market
  • FDA approval decisions for AXS-07 and AXS-14 create significant regulatory catalysts
  • Phase 3 clinical trial readouts for Alzheimer’s disease agitation influence valuation
  • Commercial scaling costs and R&D spending impact path to sustained profitability
Piotroski VR‑10 (Strict) 3.0
Net Income: -188.3m TTM > 0 and > 6% of Revenue
FCF/TA: -0.10 > 0.02 and ΔFCF/TA 9.93 > 1.0
NWC/Revenue: 24.28% < 20% (prev 58.02%; Δ -33.73% < -1%)
CFO/TA -0.10 > 3% & CFO -70.7m > Net Income -188.3m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 1.39 > 1.5 & < 3
Outstanding Shares: last quarter (51.2m) vs 12m ago 4.76% < -2%
Gross Margin: 92.60% > 18% (prev 0.91%; Δ 9.17k% > 0.5%)
Asset Turnover: 108.1% > 50% (prev 72.43%; Δ 35.68% > 0%)
Interest Coverage Ratio: -34.13 > 6 (EBITDA TTM -172.7m / Interest Expense TTM 5.31m)
Altman Z'' -8.72
A: 0.24 (Total Current Assets 611.2m - Total Current Liabilities 439.2m) / Total Assets 713.6m
B: -1.92 (Retained Earnings -1.37b / Total Assets 713.6m)
C: -0.28 (EBIT TTM -181.2m / Avg Total Assets 655.1m)
D: -2.08 (Book Value of Equity -1.37b / Total Liabilities 659.0m)
Altman-Z'' Score: -8.72 = D
Beneish M -2.86
DSRI: 0.95 (Receivables 251.1m/161.4m, Revenue 708.2m/432.2m)
GMI: 0.99 (GM 92.60% / 91.49%)
AQI: 0.88 (AQ_t 0.12 / AQ_t-1 0.13)
SGI: 1.64 (Revenue 708.2m / 432.2m)
TATA: -0.16 (NI -188.3m - CFO -70.7m) / TA 713.6m)
Beneish M-Score: -2.86 (Cap -4..+1) = A
What is the price of AXSM shares? As of May 21, 2026, the stock is trading at USD 230.62 with a total of 639,984 shares traded.
Over the past week, the price has changed by -2.00%, over one month by +22.22%, over three months by +25.53% and over the past year by +112.85%.
Is AXSM a buy, sell or hold? Axsome Therapeutics has received a consensus analysts rating of 4.74. Therefore, it is recommended to buy AXSM.
  • StrongBuy: 14
  • Buy: 5
  • Hold: 0
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the AXSM price?
Analysts Target Price 270.3 17.2%
Axsome Therapeutics (AXSM) - Fundamental Data Overview as of 21 May 2026
P/E Forward = 333.3333
P/S = 16.4696
P/B = 213.6843
Revenue TTM = 708.2m USD
EBIT TTM = -181.2m USD
EBITDA TTM = -172.7m USD
Long Term Debt = 117.8m USD (from longTermDebt, last quarter)
Short Term Debt = 70.6m USD (from shortTermDebt, last quarter)
Debt = 216.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -88.4m USD (from netDebt column, last quarter)
Enterprise Value = 11.58b USD (11.66b + Debt 216.7m - CCE 305.1m)
Interest Coverage Ratio = -34.13 (Ebit TTM -181.2m / Interest Expense TTM 5.31m)
EV/FCF = -163.1x (Enterprise Value 11.58b / FCF TTM -71.0m)
FCF Yield = -0.61% (FCF TTM -71.0m / Enterprise Value 11.58b)
FCF Margin = -10.02% (FCF TTM -71.0m / Revenue TTM 708.2m)
Net Margin = -26.59% (Net Income TTM -188.3m / Revenue TTM 708.2m)
Gross Margin = 92.60% ((Revenue TTM 708.2m - Cost of Revenue TTM 52.4m) / Revenue TTM)
Gross Margin QoQ = 92.30% (prev 93.71%)
Tobins Q-Ratio = 16.22 (Enterprise Value 11.58b / Total Assets 713.6m)
Interest Expense / Debt = 0.55% (Interest Expense 1.19m / Debt 216.7m)
Taxrate = 21.0% (US default 21%)
NOPAT = -143.2m (EBIT -181.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.39 (Total Current Assets 611.2m / Total Current Liabilities 439.2m)
Debt / Equity = 3.97 (Debt 216.7m / totalStockholderEquity, last quarter 54.6m)
 Debt / EBITDA = 0.51 (negative EBITDA) (Net Debt -88.4m / EBITDA -172.7m)
 Debt / FCF = 1.25 (negative FCF - burning cash) (Net Debt -88.4m / FCF TTM -71.0m)
 Total Stockholder Equity = 72.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -28.74% (Net Income -188.3m / Total Assets 713.6m)
RoE = -260.0% (Net Income TTM -188.3m / Total Stockholder Equity 72.4m)
RoCE = -95.25% (EBIT -181.2m / Capital Employed (Equity 72.4m + L.T.Debt 117.8m))
 RoIC = -55.04% (negative operating profit) (NOPAT -143.2m / Invested Capital 260.1m)
 WACC = 7.30% (E(11.66b)/V(11.88b) * Re(7.43%) + D(216.7m)/V(11.88b) * Rd(0.55%) * (1-Tc(0.21)))
Discount Rate = 7.43% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares (quarterly) Correlation: 100.00 | Cagr: 3.55%
 [DCF] Fair Price = unknown (Cash Flow -71.0m)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: -2.52 | # QB: -1
Revenue Correlation: 99.36 | Revenue CAGR: 61.29% | SUE: 0.12 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.82 | Chg30d=-47.48% | Revisions=-25% | Analysts=8
EPS next Quarter (2026-09-30): EPS=-0.34 | Chg30d=-471.67% | Revisions=-50% | Analysts=8
EPS current Year (2026-12-31): EPS=-1.71 | Chg30d=-63.73% | Revisions=-40% | GrowthEPS=+50.9% | GrowthRev=+54.4%
EPS next Year (2027-12-31): EPS=5.89 | Chg30d=-3.21% | Revisions=+11% | GrowthEPS=+445.1% | GrowthRev=+61.7%
[Analyst] Revisions Ratio: -50%